J Gong1, N Chen, Q Zhou, B Yang, Y Wang, X Wang. 1. Pathology Department, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.
Abstract
BACKGROUND: Malignant melanoma is highly resistant to current treatments. The inhibitor of apoptosis protein (IAP) family member, melanoma IAP (ML-IAP), is overexpressed in some melanoma cell lines, rendering them resistant to apoptotic signals. Targeting ML-IAP is a promising approach to treating melanoma. However, the status of ML-IAP expression in human melanoma tissues and the difference in expression between melanoma and melanocytic naevus are not known. AIMS: To investigate these issues. METHODS: ML-IAP expression in 48 archived patient samples (34 melanomas and 14 dermal naevi) was assessed by immunohistochemistry and by in situ hybridisation and reverse transcription polymerase chain reaction (RT-PCR) assays developed for the study. RESULTS: Expression of ML-IAP was detected in 47.6-70.6% (10 of 21 to 24 of 34) of the melanomas, varying with detection methods. The expression rate in melanoma was much higher than that in melanocytic naevus (10.0-21.4%; one of 10 to three of 14). No significant difference was seen between primary and secondary melanomas. ML-IAP expression rates assessed by the three methods were in agreement. CONCLUSIONS: The ML-IAP expression rate in archived melanoma tissues is around 50-70%, with no difference between primary and secondary melanomas. A small number of dermal naevi ( approximately 20%) also expressed ML-IAP.
BACKGROUND:Malignant melanoma is highly resistant to current treatments. The inhibitor of apoptosis protein (IAP) family member, melanoma IAP (ML-IAP), is overexpressed in some melanoma cell lines, rendering them resistant to apoptotic signals. Targeting ML-IAP is a promising approach to treating melanoma. However, the status of ML-IAP expression in humanmelanoma tissues and the difference in expression between melanoma and melanocytic naevus are not known. AIMS: To investigate these issues. METHODS:ML-IAP expression in 48 archived patient samples (34 melanomas and 14 dermal naevi) was assessed by immunohistochemistry and by in situ hybridisation and reverse transcription polymerase chain reaction (RT-PCR) assays developed for the study. RESULTS: Expression of ML-IAP was detected in 47.6-70.6% (10 of 21 to 24 of 34) of the melanomas, varying with detection methods. The expression rate in melanoma was much higher than that in melanocytic naevus (10.0-21.4%; one of 10 to three of 14). No significant difference was seen between primary and secondary melanomas. ML-IAP expression rates assessed by the three methods were in agreement. CONCLUSIONS: The ML-IAP expression rate in archived melanoma tissues is around 50-70%, with no difference between primary and secondary melanomas. A small number of dermal naevi ( approximately 20%) also expressed ML-IAP.
Authors: M S Soengas; P Capodieci; D Polsky; J Mora; M Esteller; X Opitz-Araya; R McCombie; J G Herman; W L Gerald; Y A Lazebnik; C Cordón-Cardó; S W Lowe Journal: Nature Date: 2001-01-11 Impact factor: 49.962
Authors: Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett Journal: Cancer Biol Ther Date: 2017-05-17 Impact factor: 4.742
Authors: Jun Zhou; Noah K Yuen; Qian Zhan; Elsa F Velazquez; George F Murphy; Anita Giobbie-Hurder; F Stephen Hodi Journal: Cancer Immunol Immunother Date: 2011-10-28 Impact factor: 6.968